Shadeequa D. Miller

Learn More
BACKGROUND Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody, in asthmatics. METHODS Study 1: adults (18-65 years) with(More)
Consumer health information technology (CHIT) applications have the potential to improve overall care quality for older adults. The design and development of CHIT applications requires an understanding of the current and future personal health information management (PHIM) activities occurring in home and community settings. Building a better understanding(More)
  • 1